P
2.03
0.08 (4.10%)
| 前收盘价格 | 1.95 |
| 收盘价格 | 2.02 |
| 成交量 | 880,157 |
| 平均成交量 (3个月) | 1,135,093 |
| 市值 | 266,256,832 |
| 价格/销量 (P/S) | 66.00 |
| 股市价格/股市净资产 (P/B) | 1.42 |
| 52周波幅 |
| 营业利益率 (TTM) | -2,025.74% |
| 稀释每股收益 (EPS TTM) | -1.65 |
| 总债务/股东权益 (D/E MRQ) | 26.64% |
| 流动比率 (MRQ) | 5.58 |
| 营业现金流 (OCF TTM) | -122.86 M |
| 杠杆自由现金流 (LFCF TTM) | -114.57 M |
| 资产报酬率 (ROA TTM) | -51.51% |
| 股东权益报酬率 (ROE TTM) | -136.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Prime Medicine, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 23.91% |
| 机构持股比例 | 59.05% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 12.00 (Chardan Capital, 491.13%) | 购买 |
| 中 | 10.00 (392.61%) | |
| 低 | 1.50 (Citigroup, -26.11%) | 保留 |
| 平均值 | 7.90 (289.16%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 1.59 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 27 May 2025 | 1.50 (-26.11%) | 保留 | 1.23 |
| JMP Securities | 20 May 2025 | 6.00 (195.57%) | 购买 | 1.18 |
| Chardan Capital | 19 May 2025 | 12.00 (491.13%) | 购买 | 1.34 |
| 20 Mar 2025 | 16.00 (688.18%) | 购买 | 2.01 | |
| HC Wainwright & Co. | 19 Mar 2025 | 10.00 (392.61%) | 购买 | 2.00 |
| 03 Mar 2025 | 10.00 (392.61%) | 购买 | 2.24 | |
| Citizens Capital Markets | 04 Mar 2025 | 10.00 (392.61%) | 购买 | 2.21 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合